Dawn Eichenfield, MD, PhD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Researcher
    Ineligible company:
    Johnson and Johnson
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Nobelpharma
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Ortho Dermatologics
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Palvella
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Pelthos
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Regeneron
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Sanofi
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Sanofi
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Verrica
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Verrica
    Date added:
    10/20/2026
    Date updated:
    10/20/2026

Pages

Return to FACIAL ANGIOFIBROMAS IN TUBEROUS SCLEROSIS COMPLEX Recognition, Treatment and Case-Based Management